ANI Pharmaceuticals Q4 EPS Soars 43%, Rare Disease Sales Jump 50.8%
ANI Pharmaceuticals reported Q4 adjusted EPS of $2.33, beating estimates, and revenues rose 29.6% to $247.1 million while net income swung to $27.5 million from a prior-year loss. Rare Disease sales jumped 50.8% to $131.3 million and full-year 2026 revenue guidance tops $1 billion.
1. Fourth-Quarter Results
ANI Pharmaceuticals delivered adjusted earnings of $2.33 per share in Q4, up from $1.63 a year ago, topping the $2.00 consensus. Net revenues climbed 29.6% to $247.1 million and net income turned positive at $27.5 million versus a $10.7 million loss a year earlier.
2. Rare Disease Segment Performance
The Rare Disease business achieved 50.8% year-over-year growth to $131.3 million, driven by increased Cortrophin Gel demand. Management plans to expand into underpenetrated specialty indications and launch a dedicated acute gouty arthritis flares organization.
3. Fiscal 2026 Guidance
ANI expects total sales of $1.055–$1.115 billion in fiscal 2026, with Rare Disease representing approximately 60% of revenue. Adjusted EPS is projected at $8.83–$9.34 and adjusted EBITDA at $275–$290 million, led by $540–$575 million in Cortrophin Gel and $78–$83 million in ILUVIEN sales.
4. Analyst Outlook & Technical Indicators
Analysts maintain a buy rating with an average target of $95.50 and recent upgrades from multiple firms. The stock trades above its 20-day moving average but below its 100-day average, with a neutral RSI of 50.00 and a bearish MACD suggesting mixed momentum.